Three of a kind in glucagon game as FDA turns over Zealand’s card

Three of a kind in glucagon game as FDA turns over Zealand’s card

datetime
BioWorld
We’re launching at the right time,” said Frank Sanders, president of Zealand Pharma A/S’s business in the U.S., in the wake of clearance granted by the FDA for the Copenhagen, Denmark-based firm’s glucagon analogue Zegalogue (dasiglucagon) in severe hypoglycemia.
Health
Read Article